Eli Lilly and Company (NYSE:LLY) Shares Sold by Thompson Siegel & Walmsley LLC

VaselineSeptember 17, 2024

0 4 minutes read

Eli Lilly and Company logo Thompson Siegel & Walmsley LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 37.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. . The fund owned 2,146 shares of the company’s stock after selling 1,299 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Eli Lilly and Company were worth $1,943,000 at the end of the most recent quarter.

A number of other institutional investors have recently added to or reduced their stakes in the company. Rock Point Advisors LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $282,000. Wilkins Investment Counsel Inc. boosted its stake in Eli Lilly and Company by 8.4% in the second quarter. Wilkins Investment Counsel Inc. now owns 3,104 shares of the company’s stock valued at $2,810,000 after purchasing an additional 240 shares during the period. Diversify Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at $4,067,000. Seven Mile Advisory boosted its holdings in shares of Eli Lilly and Company by 4.0% in the second quarter. Seven Mile Advisory now owns 1,136 shares of the company’s stock valued at $1,028,000 after acquiring an additional 44 shares in the last quarter. Finally, Vista Capital Partners Inc. raised its stake in shares of Eli Lilly and Company by 5.7% during the second quarter. Vista Capital Partners Inc. now owns 1,069 shares of the company’s stock worth $968,000 after acquiring an additional 58 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s shares.

Eli Lilly and Company stock rose 0.0%

Shares of NYSE:LLY opened at $924.05 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.11, and a debt-to-equity ratio of 1.74. The company has a market cap of $878.22 billion, a P/E ratio of 136.09, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The stock’s fifty-day simple moving average is $897.24, and its 200-day simple moving average is $835.09.

Want more great investment ideas?

Eli Lilly and Company (NYSE:LLY – Get Your Free Report ) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company announces dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were paid a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15. This represents an annualized dividend of $5.20 and a yield of 0.56%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Changes in Analyst Ratings

A number of brokerages have recently commented on LLY. Citigroup began coverage on shares of Eli Lilly and Company in a research report on Friday. They issued a “buy” rating and a $1,060.00 price objective for the company. Guggenheim boosted their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday. Finally, Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday. August 14. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of “Moderate Buy” and a consensus price target of $977.35, based on data from MarketBeat.

Read our latest report on LLY

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 9,671 shares of Eli Lilly and Company stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $902.67, for a total value of $8,729,721.57. Following the completion of the sale, the insider now owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Over the last three months, insiders have sold 451,900 shares of company stock worth $418,732,178. Insiders own 0.13% of the company’s shares.

Eli Lilly and Company Company Profile

(Free report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.